Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, Pathak S, Anthony MS, Layton JB. Natural history and clinical outcomes in patients with Alzheimer's disease-related psychosis in the United States. Presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2024; March 5, 2024. Lisbon, Portugal.
Layton JB, Forns Guzman J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Mortality in patients with Parkinson's disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023 Feb 1;46(2):195-208. doi: 10.1007/s40264-022-01260-6
Forns J, Danysh HE, McQuay LJ, Turner ME, Dempsey C, Anthony MS, Demos G, Layton JB. Clinical outcomes and treatment patterns of older adults with dementia‑related psychosis by dementia type in the United States. BMC geriatr. 2022 Oct 6;22(1):784. doi: 10.1186/s12877-022-03489-3.
Bradley Layton J, McQuay L, Forns J, Danysh H, Dempsey C, Anthony MS, Turner ME. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease–related psychosis. Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark. Previously presented at the 2022 American Society of Clinical Psychopharmacology (ASCP).
Layton JB, McQuay L, Forns J, Danysh HE, Dempsey C, Anthony MS, Turner ME. Risk of mortality associated with pimavanserin compared with atypical antipsychotics in patients with Parkinson's disease–related psychosis. Presented at the 2022 American Society of Clinical Psychopharmacology (ASCP); May 31, 2022. Scottsdale, AZ.
Forns J, Danysh H, McQuay L, Turner ME, Dempsey C, Anthony M, Layton B. Natural history of dementia-related psychosis and antipsychotic treatment patterns in older adults in the United States. Presented at the International Conference on Alzheimer's and Parkinson's Diseases 2022; March 18, 2022. Barcelona, Spain.
Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, Danysh HE, Ritchey ME, Demos G. Falls and fractures in patients with Parkinson's Disease–related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022 Mar;9(1):9-22. doi: 10.1007/s40801-021-00284-1
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021 Jan 27. doi: 10.1371/journal.pone.0246121
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Forns J, Layton JB, Ritchey ME. Identifying psychosis in patients with dementia: not a hallucination or delusion, the challenge really exists. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 24(S2):214. doi: 10.1002/pds.4864